Department of Dermatology, Peking University First Hospital, 8 Xishiku Street, Beijing 100034, China.
Department of Dermatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Eur J Dermatol. 2024 Apr 1;34(2):176-181. doi: 10.1684/ejd.2024.4701.
Ixekizumab is a monoclonal antibody targeting interleukin-17A that has shown significant improvement in alleviating psoriasis. However, data is sparse on the efficacy of ixekizumab in psoriasis patients in China. To investigate the efficacy of ixekizumab in Chinese psoriasis patients. Patients with moderate-to-severe psoriasis were retrospectively investigated from April 2020 to October 2020. A total of 16 patients were treated with 80 mg ixekizumab every two weeks after a 160-mg loading dose. Efficacy was assessed using the Psoriasis Activity and Severity Index (PASI), static Physician's Global Assessment (sPGA) and Dermatology Life Quality Index (DLQI) at Weeks 0, 1, 2, 3, 4, 8, and 12. All patients showed excellent response to the treatment. Compared to baseline level, the improvement was significant and statistically significant at Week 1, 2, 4, 8 and 12 (p<0.05). Of the patients, 18.75% reported sPGA 0/1 (clear or almost clear skin) as early as Week 2, and the percentage of patients who reported sPGA 0/1 reached 100% at Week 12. Moreover, the DLQI decreased gradually coinciding with improvement in PASI and sPGA. The head/neck regions showed the fastest improvements, followed by the trunk and the arms/legs. During the 12-week period, no serious adverse effects occurred. Our results indicate that the treatment of ixekizumab was safe and effective in psoriasis patients in China.
依奇珠单抗是一种靶向白细胞介素-17A 的单克隆抗体，已显示出在缓解银屑病方面的显著改善。然而，在中国银屑病患者中，依奇珠单抗的疗效数据较为有限。本研究旨在探讨依奇珠单抗在中国银屑病患者中的疗效。我们回顾性调查了 2020 年 4 月至 2020 年 10 月期间中度至重度银屑病患者。所有患者在给予 160mg 负荷剂量后，每两周接受 80mg 依奇珠单抗治疗。在第 0、1、2、3、4、8 和 12 周时，采用银屑病面积和严重程度指数（PASI）、静态医师整体评估（sPGA）和皮肤病生活质量指数（DLQI）评估疗效。所有患者对治疗均有良好反应。与基线水平相比，第 1、2、4、8 和 12 周时改善显著且具有统计学意义（p<0.05）。第 2 周即有 18.75%的患者报告 sPGA 0/1（皮肤完全清除或几乎完全清除），第 12 周时报告 sPGA 0/1 的患者比例达到 100%。此外，DLQI 随着 PASI 和 sPGA 的改善而逐渐下降。头部/颈部区域改善最快，其次是躯干和手臂/腿部。在 12 周期间，未发生严重不良反应。我们的结果表明，依奇珠单抗治疗中国银屑病患者安全且有效。
